Safety and Exploratory Efficacy Study of SF0166 in the Treatment of Neovascular Age-Related Macular Degeneration (AMD)

NCT02914639 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

44

Enrollment

INDUSTRY

Sponsor class

Conditions

Age-Related Macular Degeneration

Interventions

DRUG: SF0166 Topical Ophthalmic Solution

Sponsor

OcuTerra Therapeutics, Inc.